Genmab launches $97 per share tender offer for Merus

Genmab A/S (NASDAQ: GMAB) announced it has commenced a cash tender offer to purchase all outstanding common shares of Merus N.V. (NASDAQ: MRUS) for $97.00 per share through its wholly owned subsidiary Genmab Holding II B.V.

The tender offer follows a transaction agreement dated September 29, 2025, between the companies. Genmab filed a tender offer statement on Schedule TO with the U.S. Securities and Exchange Commission, while Merus filed a Schedule 14D-9 recommending shareholders accept the offer.

The offer will expire at 5:00 p.m. New York time on December 11, 2025, unless extended under the transaction agreement terms. If conditions are met, Genmab will commence a subsequent offering period for at least 10 business days following the initial expiration.

The offer is not subject to financing conditions but includes other requirements outlined in the SEC filing, including a minimum tender condition. The transaction does not require regulatory approval beyond standard tender offer procedures.

Copenhagen-based Genmab operates as an international biotechnology company focused on antibody therapeutics. The company was established in 1999 and maintains operations across North America, Europe and Asia Pacific.

Merus develops antibody-based cancer treatments and is headquartered in the Netherlands with operations in the United States. The company trades on NASDAQ under the ticker MRUS.

Shareholders can obtain tender offer documents through the SEC website or by contacting information agent Innisfree M&A Incorporated. The documents contain detailed terms and conditions for the proposed acquisition.

You May Also Be Interested In